NCT01001832 - Efficacy, Pharmacokinetics, Safety, and Immunogenicity Study of Abatacept Administered Subcutaneously to Treat Rheumatoid Arthritis in Japanese Patients | Biotech Hunter

Enrollment

118

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

February 28, 2011

Study Completion Date

October 31, 2012

Conditions

Rheumatoid Arthritis

Interventions

DRUG

Intravenous (IV) abatacept

IV vial, 125-mg infusions on Days 1, 15, and 29, and every 28 days thereafter until Day 141.

DRUG

Subcutaneous (SC) abatacept

Solution in prefilled syringes, SC, 125 mg, once weekly, for 169 days and then for 52 weeks

Trial Locations (33)

1138519

Local Institution, Bunkyo-Ku

1608582

Local Institution, Shinjuku-Ku

1648541

Local Institution, Nakano-Ku

2220036

Local Institution, Yokohama

2360037

Local Institution, Yokohama

2520392

Local Institution, Sagamihara-Shi

2868523

Local Institution, Narita-Shi

3160035

Local Institution, Hitachi-Shi

3290498

Local Institution, Shimotsuke-Shi

3291193

Local Institution, Utsunomiya

3500495

Local Institution, Iruma-Gun

3508550

Local Institution, Kawagoe-Shi

3591111

Local Institution, Tokorozawa-Shi

3640026

Local Institution, Kitamoto-Shi

3700053

Local Institution, Takasaki-Shi

3718511

Local Institution, Maebashi

3808582

Local Institution, Nagano

4208623

Local Institution, Shizuoka

4308558

Local Institution, Hamamatsu

5990212

Local Institution, Hannan-Shi

6500001

Local Institution, Kobe

6731462

Local Institution, Kato-Shi

6792414

Local Institution, Kanzaki-Gun

7128044

Local Institution, Kurashiki-Shi

7390002

Local Institution, Higashi-Hiroshima-Shi

8078555

Local Institution, Kitakyushu-Shi

8108563

Local Institution, Fukuoka

8308543

Local Institution, Kurume-Shi

8900067

Local Institution, Kagoshima

0608604

Local Institution, Sapporo

0608648

Local Institution, Sapporo

0630005

Local Institution, Sapporo

0630811

Local Institution, Sapporo